Suchergebnisse - "Palermo, Federica"

PubPharm (13)

1

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence : PURITY study

enthalten in: BMC cancer | 2024

von Niger, M. | Nichetti, F. | Fornaro, L. | +34

2

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

enthalten in: BMC cancer | 2024

von Niger, M. | Nichetti, F. | Fornaro, L. | +34

3

Mind the gap with Europe. Why public interest cannot be a good reason to perform observational and epidemiological research?

enthalten in: Tumori | 2024

von Cagnazzo, C. | Ficara, B. | Palermo, F. | +1

4

Observational studies - The Cinderella of the Italian research system

enthalten in: Tumori | 2023

von Cagnazzo, C. | Basiricò, M. | Palermo, F. | +1

5

Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer : An individual patient data pooled analysis of randomised clinical trials

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Raimondi, A. | Nichetti, F. | Stahler, A. | +16

6

Adverse events during first-line treatments for mCRC : The Toxicity over Time (ToxT) analysis of three randomised trials

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Boccaccino, A. | Rossini, D. | Raimondi, A. | +16

CommentOn: Lancet Haematol. 2020 Jun;7(6):e490-e497. - PMID 32470440

7

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer : The MAYA Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Morano, F. | Raimondi, A. | Pagani, F. | +30

8

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer : The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study

enthalten in: Cancers | 2021

von Raimondi, A. | Palermo, F. | Prisciandaro, M. | +29

9

The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Manca, P. | Corallo, S. | Busico, A. | +22

10

Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Manca, P. | Corallo, S. | Randon, G. | +24